General
Preferred name
SURAMIN
Synonyms
SURAMIN HEXASODIUM ()
Salt suramin, monosodiu ()
Suramin sodium salt ()
Suramin hexasodium salt ()
BAY-205 ()
NF-060 ()
suramin, NIH ()
Suramin (sodium salt) ()
Suramin (hexasodium salt) ()
Suraminum natricum ()
Suramina de sodio ()
Nagananinum ()
BAYER-205 ()
Suramin sodium ()
FOURNEAU 309 ()
NSC-758165 ()
FOURNEAU-309 ()
Suramine sodique ()
CI-1003 ()
Naphuride ()
Farma ()
Naganol ()
NSC-34936 ()
Metaret ()
Suramine ()
FARMA-939 ()
Fourneau ()
P&D ID
PD009369
CAS
129-46-4
145-63-1
Tags
available
drug candidate
drug
obsolete probe
Drug indication
African trypanosomiasis
Coronavirus Disease 2019 (COVID-19)
Trypanosomiasis
non-small cell lung carcinoma
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor[1]. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 ¦ÌM), and SirT5 (IC50=22 ¦ÌM)[2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 ¦ÌM)[3][4]. Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor[5]. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent[6][7][8].
DESCRIPTION
Suramin is an antiparasitic drug. It is also used in research as a broad-spectrum P2 receptor antagonist and as a ryanodine receptor agonist .
DESCRIPTION
Suramin is an antiparasitic drug. It is also used in research as a broad-spectrum P2 receptor antagonist and as a ryanodine receptor agonist .
Evidence from studies in mice , and from an early phase clinical trial suggest antipurinergic therapy (using suramin or other antipurinergic compounds) as a potential lead in the search for pharmacotherapeutic intervention in children with autism spectrum disorder (see Phase 1/2 clinical trial NCT02508259). (GtoPdb)
Evidence from studies in mice , and from an early phase clinical trial suggest antipurinergic therapy (using suramin or other antipurinergic compounds) as a potential lead in the search for pharmacotherapeutic intervention in children with autism spectrum disorder (see Phase 1/2 clinical trial NCT02508259). (GtoPdb)
DESCRIPTION
Non-selective P2 antagonist
(Tocriscreen Total)
DESCRIPTION
P2X and P2Y receptor antagonist; antiparasitic; anti-tumor agent
(LOPAC library)
DESCRIPTION
Suramin Sodium Salt (BAY-205) is a sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
4
Organisms
15
Compound Sets
26
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Guide to Pharmacology
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Obsolete Compounds
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Pathogen Box
The Spectrum Collection
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
73
Molecular Weight
1296.05
Hydrogen Bond Acceptors
17
Hydrogen Bond Donors
12
Rotatable Bonds
16
Ring Count
8
Aromatic Ring Count
8
cLogP
6.74
TPSA
483.75
Fraction CSP3
0.04
Chiral centers
0.0
Largest ring
6.0
QED
0.04
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Disease
REFERENCE COMPOUNDS
Selectivity
P2X, P2Y
Target
P2Y Receptor
Apoptosis
Parasite
phosphatase
Reverse Transcriptase
SARS-CoV
Sirtuin
Topo II
Topoisomerase
Interleukin Related
F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5
DNA/RNA Synthesis,Sirtuin,Topoisomerase
Pathway
GPCR/G protein
Immunology/Inflammation
Chromatin/Epigenetic
DNA Damage/DNA Repair
Metabolism
Microbiology/virology
Anti-infection
Cell Cycle/DNA Damage
Epigenetics
Metabolic Enzyme/Protease
Indication
African trypanosomiasis, onchocerciasis
MOA
DNA synthesis inhibitor
Therapeutic Class
Antinematodal Agents
Antiviral Agents
Source data
